On a positive note, Nasdaq's adjusted operating expenses were marginally lower than anticipated, reported at $556 million ...

- Citi acted as Note Trustee, Principal Paying Agent, and Calculation Agent for CCMM’s first bond issuance LONDON--(BUSINESS WIRE)-- Citi Issuer Services has completed the settlement of the ...

Citi analyst Alicia Yap opened a “90-day positive catalyst watch” on shares of JD.com (JD) while reiterating a Buy rating on the name with a $51 price target The company kicked off the new ...

Citi initiated coverage of ServiceTitan (TTAN) with a Neutral rating and $109 price target ServiceTitan is a vertical software-as-a-service company focused on providing purpose-built software for ...

Oppenheimer lowered the firm’s price target on Citi to $102 from $110 and keeps an Outperform rating on the shares. For banks, the trend lines in 2025 “seem well established,” and ...

Citi analyst Anthony Pettinari upgraded Azek (AZEK) to Buy from Neutral with a price target of $60, up from $51. The firm cites is its above-consensus 2025 estimates, and attractive relative ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...

Citi analyst Vikram Bagri upgraded HASI (HASI) to Buy from Neutral with a $36 price target The firm says the company is more insulated from potential policy changes. Utility scale companies are ...

The emergence of DeepSeek AI models draws into question the narrative of US exceptionalism, raising concerns about the ...

Atlassian (NASDAQ: TEAM) stock enjoyed a modest price ... Commenting on the moves, Citi calls the price hikes "aggressive," which could suggest that Atlassian is making a mistake -- but that's ...

Citi lowered the firm’s price target on Generac (GNRC) to $162 from $172 and keeps a Neutral rating on the shares. The firm also added a “90-day negative catalyst watch” on the shares. Citi ...

Citi initiated coverage of EyePoint (EYPT) with a Buy rating and $33 price target. The firm expects both EyePoint and competitor Ocular Therapeutix (OCUL) to capture meaningful share in wet age ...